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We’re all well aware of the problems of doing randomised clinical trials 
in paediatrics but are we as aware of some alternative approaches 
that have been used?1
‘Sequential design’ studies look at comparing a series of treatments 
against each other, switching to the ‘better’ arm and comparing against 
the next candidate as time progresses. They need quickly and easily 
available outcomes and tend to be usable only for short-course treat-
ments but they’ve been estimated to reduce sample sizes by about 25%.
‘Adaptive design’ begins by pitting all the contenders against each 
other and dropping off the weakest. It can then roll onwards with the 
final two into a more ‘traditional’ trial design. Again, this needs pretty 
rapid outcomes and fairly short-course treatments, but reduces numbers 
to only half of those needed in repeated traditional design trials.
‘Response adapted’ designs are intriguing. These include the with-
drawal-enriched design—where everyone gets the treatment to start 
with, then those who show response are randomised to having placebo 
or carrying on with therapy. This is tricky with ethics—if you’ve shown 
it to work can you stop?—and has the risk of carryover effects, and 
doesn’t work for curative treatments. Another variation is the three-
stage design, which starts with a randomisation to treatment/placebo. 
Stage 2 is taking the non-responders to placebo, and randomising those 
again to placebo/treatment, and stage 3, where only those who have 
responded to treatment are taken and randomised to placebo/carry-on 
(like the withdrawal design). This works well with chronic conditions 
where therapy is not disease modifying, but changes outcomes for a 
short period.
‘Placebo-phase’ randomisations are appealing for therapies with 
a good chance of success. These randomise participants to all receive 
the treatment … the randomisation is about ‘when’ to get it … with 
variable placebo phases before treatment is commenced. This offers 
the opportunity to treat every child, and still manage to estimate the 
effect of a therapy. This does rely on (a) you not requiring immediate 
disease-altering treatment and (b) the disease process not changing 
massively over time so the ‘later’ ones have more disease to get rid 
of than the earlier ones.
‘Bayesian approaches’ are the oddest to think about. They start from 
the principle that we do not have a 50% knowledge about a therapy, 
but based on adult evidence and possibly prior phase II child studies, 
we actually believe it’s about 60%–70% (or whatever) effective. The 
trial analysis then ‘builds’ on this ‘prior knowledge’ to come up with an 
answer based on the assumptions and the data. This can greatly reduce 
the amount of people needed in the trial, but can feel very suspect. 
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